Under Armour, Inc. (UAA)’s Insider William Mcdermott Sells 6,508 Shares; IMMUNOVACCINE ORDINARY SHARES CANAD (IMMVF) SI Decreased By 2.15%

May 8, 2018 - By Linda Rogers

ImmunoVaccine Inc. (OTCMKTS:IMMVF) Logo

IMMUNOVACCINE INC ORDINARY SHARES CANAD (OTCMKTS:IMMVF) had a decrease of 2.15% in short interest. IMMVF’s SI was 50,000 shares in May as released by FINRA. Its down 2.15% from 51,100 shares previously. With 11,800 avg volume, 4 days are for IMMUNOVACCINE INC ORDINARY SHARES CANAD (OTCMKTS:IMMVF)’s short sellers to cover IMMVF’s short positions. The SI to IMMUNOVACCINE INC ORDINARY SHARES CANAD’s float is 0.04%. The stock decreased 1.61% or $0.0281 during the last trading session, reaching $1.7119. About shares traded. ImmunoVaccine Inc. (OTCMKTS:IMMVF) has 0.00% since May 8, 2017 and is . It has underperformed by 11.55% the S&P500.

More notable recent Under Armour, Inc. (NYSE:UAA) news were published by: Seekingalpha.com which released: “Buy Under Armour For 2019 Recovery” on May 06, 2018, also 247Wallst.com with their article: “How Under Armour Managed to Pull Off a Decent Q1 Report” published on May 01, 2018, Seekingalpha.com published: “UnderArmour Earnings Preview” on April 29, 2018. More interesting news about Under Armour, Inc. (NYSE:UAA) were released by: Benzinga.com and their article: “Under Armour’s Existential Crisis: Niche Player Or Global Competitor?” published on May 02, 2018 as well as 247Wallst.com‘s news article titled: “World’s 10 Largest Data Breaches in 2018 Q1” with publication date: May 08, 2018.

Investors sentiment increased to 0.82 in 2017 Q4. Its up 0.01, from 0.81 in 2017Q3. It increased, as 57 investors sold Under Armour, Inc. shares while 114 reduced holdings. 43 funds opened positions while 98 raised stakes. 143.44 million shares or 7.95% more from 132.88 million shares in 2017Q3 were reported. Baystate Wealth Management invested 0% of its portfolio in Under Armour, Inc. (NYSE:UAA). Lincoln National has 15,868 shares for 0.01% of their portfolio. Sun Life Fincl Inc invested in 0% or 1,407 shares. Geode Mgmt Ltd accumulated 1.89 million shares. Jane Street Group Inc Limited Co accumulated 0.02% or 589,589 shares. Iconiq Limited Liability Corporation reported 380,141 shares or 0.57% of all its holdings. California-based Franklin Inc has invested 0% in Under Armour, Inc. (NYSE:UAA). Roffman Miller Assoc Pa invested in 22,033 shares or 0.04% of the stock. The Japan-based Sumitomo Mitsui Asset Co Ltd has invested 0% in Under Armour, Inc. (NYSE:UAA). Dnb Asset Mngmt As holds 0% of its portfolio in Under Armour, Inc. (NYSE:UAA) for 18,622 shares. Perigon Wealth Mngmt Lc holds 0.01% of its portfolio in Under Armour, Inc. (NYSE:UAA) for 1,198 shares. Farmers & Merchants Investments reported 77 shares. Cornerstone Advisors Incorporated reported 0.04% in Under Armour, Inc. (NYSE:UAA). Susquehanna Group Inc Ltd Liability Partnership invested in 0.01% or 2.41 million shares. Chevy Chase Trust Holdings invested 0.01% of its portfolio in Under Armour, Inc. (NYSE:UAA).

Under Armour Inc’s shareholder William Mcdermott made a sale of 6,508 shares of the stock in a trade dated 07-05-2018. The mentioned shares were unloaded at the average stock price of $17.7, for an aggregate sell of $115,214. In the last month, he also sold 6,349 shares with a market value $102,096 USD. For more info of this trade please open the SEC’s document available for free here. The probability of this sell staying hidden is very little as it’s new, with William Mcdermott now owning 59,657 shares — that is 0.01% of the Company’s total market capitalization.

Among 12 analysts covering Under Armour (NYSE:UAA), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. Under Armour has $23 highest and $9 lowest target. $15.88’s average target is -11.14% below currents $17.87 stock price. Under Armour had 14 analyst reports since March 24, 2017 according to SRatingsIntel. The stock of Under Armour, Inc. (NYSE:UAA) has “Neutral” rating given on Friday, April 28 by UBS. The stock of Under Armour, Inc. (NYSE:UAA) earned “Underperform” rating by FBR Capital on Monday, April 3. Piper Jaffray maintained it with “Neutral” rating and $17 target in Wednesday, April 12 report. The firm has “Buy” rating by Jefferies given on Friday, March 24. The stock of Under Armour, Inc. (NYSE:UAA) earned “Neutral” rating by Wedbush on Wednesday, April 12. The stock of Under Armour, Inc. (NYSE:UAA) earned “Hold” rating by Suntrust Robinson on Wednesday, November 1. The stock of Under Armour, Inc. (NYSE:UAA) has “Hold” rating given on Tuesday, October 17 by Stifel Nicolaus. The rating was maintained by Telsey Advisory Group with “Market Perform” on Friday, April 28. The rating was maintained by Nomura with “Reduce” on Friday, November 10. The rating was upgraded by Stifel Nicolaus on Friday, December 15 to “Buy”.

Since May 3, 2018, it had 0 buys, and 2 selling transactions for $223,379 activity. $119,579 worth of Under Armour, Inc. (NYSE:UAA) was sold by SANDERS HARVEY on Thursday, May 3.

The stock increased 2.94% or $0.51 during the last trading session, reaching $17.87. About 4.97M shares traded. Under Armour, Inc. (NYSE:UAA) has declined 17.22% since May 8, 2017 and is downtrending. It has underperformed by 28.77% the S&P500.

Under Armour, Inc., together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has market cap of $7.48 billion. The firm offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes. It currently has negative earnings. It also provides various footwear products, including running, basketball, cleated, slides and performance training, and outdoor footwear.

Immunovaccine Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company has market cap of $233.50 million. The companyÂ’s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It currently has negative earnings. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer.

Under Armour, Inc. (NYSE:UAA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>